Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1037008

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Human Papillomavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps the Government is taking to ensure education for young adults on HPV vaccination and cervical screening.
tabling member constituency	Washington and Sunderland West
tabling member printed	Mrs Sharon Hodgson
uin	205851
answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>Public Health England (PHE) developed a range of materials targeted at teenagers and their parents to provide information about the human papillomavirus (HPV) vaccination programme to help them make an informed choice. Local immunisation providers should share this information and signpost teenagers and their parents to these materials when the offer of HPV vaccination is underway in schools. PHE also provides information and training materials for health professionals to ensure they can adequately respond to queries or concerns.</p><p> </p><p>In March 2019, PHE will launch a national campaign to highlight the risks of cervical cancer to encourage all eligible women to attend their cervical screening appointment.</p><p> </p><p>In addition, PHE has also worked closely with a number of charities such as Jo’s Cervical Cancer Trust and the Teenage Cancer Trust to develop lesson plans for schools to use to teach young people about cervical cancer and the HPV vaccine.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 16:14:44 answering member 4067 label Biography information for Steve Brine
tabling member	1521 label Biography information for Mrs Sharon Hodgson

1037019

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	General Practitioners: Crimes of Violence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many patients have been allocated to the Special Allocation Scheme in each year since 2010.
tabling member constituency	Ellesmere Port and Neston
tabling member printed	Justin Madders
uin	205961
answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>The following table presents the number of patients that have been removed from general practitioner (GP) practice lists in England and placed on a Special Allocation Scheme between 2016 and 2018. Data prior to April 2016 was not collected or held centrally.</p><table><tbody><tr><td><p>​Year</p></td><td><p>Special Allocation Scheme​</p></td></tr><tr><td><p>2016​</p></td><td><p>​1,252</p></td></tr><tr><td><p>​2017</p></td><td><p>2,055​</p></td></tr><tr><td><p>​2018</p></td><td><p>1,686</p></td></tr></tbody></table><p>Notes:</p><p>- 2018 includes data to November 2018.</p><p>- 2016 includes data from April to December 2016.</p><p> </p><p>NHS England has a responsibility to ensure that all patients can access good quality GP services. The Special Allocation Scheme was created to ensure that patients who have been removed from a practice patient list can continue to access healthcare services at an alternative, specific GP practice.</p><p> </p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 12:10:01 answering member 4067 label Biography information for Steve Brine
tabling member	4418 label Biography information for Justin Madders

1037022

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Additives: Regulation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions he has had with the Food Standards Agency on (a) the regulation of colouring and other food additives and (b) the role of the European Food Safety Authority in that regulation in the event that the UK leaves the EU.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	206032
answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>Our priority is to maintain the United Kingdom’s high standards of food safety. To help deliver this the Food Standards Agency (FSA) is preparing secondary legislation to ensure a functioning body of law is in place following the UK’s exit from the European Union; this includes legislation on colours added to food and other food additives.</p><p> </p><p>The intention is to lay these statutory instruments before Parliament, using powers under the EU Withdrawal Act. This legislation will provide continuity and clarity for UK food businesses, as well as reassurance for consumers that existing levels of public health protection and food safety are being maintained.</p><p> </p><p>Options for the future risk assessment and scientific advice for food and feed safety in the UK are being developed by the FSA. As part of the exit negotiations, we are seeking to continue our close working relationship with the European Food Safety Authority, whilst strengthening our existing risk assessment capacity.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 16:11:26 answering member 4067 label Biography information for Steve Brine
tabling member	4656 label Biography information for Layla Moran

1037028

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent discussions he has had with (a) NHS England (b) NICE and (c) Vertex on access to Orkambi for cystic fibrosis sufferers; and if he will make a statement.
tabling member constituency	Oxford West and Abingdon
tabling member printed	Layla Moran
uin	206035
answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>Officials in the Department have had a number of discussions with the National Institute for Health and Care Excellence (NICE) and NHS England on the availability of Orkambi. NICE and NHS England are leading the dialogue with Vertex Pharmaceuticals around access to its portfolio of cystic fibrosis medicines. It is critical that Vertex now re-engages fully with the NICE appraisal process and gives serious consideration to the portfolio deal offer that NHS England made at the end of July. This deal would provide immediate access for patients to all Vertex licensed medicines and future pipeline products once licensed and in advance of the individual NICE appraisals concluding. The Government fully supports the approach that NICE and NHS England are adopting.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 16:12:27 answering member 4067 label Biography information for Steve Brine
tabling member	4656 label Biography information for Layla Moran

1037067

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the voluntary scheme for branded medicines pricing and access: heads of agreement, published on 23 November 2018, whether NHS England’s commissioning support programme will be discontinued.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	205950
answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>It is expected that the commissioning support programme, which provides support for service development relating to medicines, as well as medical devices or other sorts of intervention, will continue for 2019/20. The new voluntary scheme for branded medicines pricing and access includes new commitments to the National Institute for Health and Care Excellence (NICE) appraisals for medicines; any implications will be considered through implementation of the new scheme.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 16:01:48 answering member 4067 label Biography information for Steve Brine
tabling member	4249 label Biography information for Anne Marie Morris

1037085

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cervical Cancer: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to introduce an epigenetics-based test for cervical cancer on the NHS.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	205920
answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>The United Kingdom National Screening Committee (UK NSC) has not reviewed the evidence for an epigenetics-based test within the cervical screening programme.</p><p> </p><p>It is important that any screening test introduced into a screening programme is based on robust published peer reviewed evidence demonstrating more good than harm. A change to the main screen test such as using epigenetics-based testing would be considered as a major programme modification to the cervical screening programme.</p><p> </p><p>Submissions to the UK NSC to consider a programme modification can be submitted throughout the year with more information available at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/uk-nsc-evidence-review-process" target="_blank">https://www.gov.uk/government/publications/uk-nsc-evidence-review-process</a></p><p> </p><p>NHS England is currently working to implement primary human papillomavirus screening in England.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 12:11:45 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

1037086

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Liothyronine: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with pharmaceutical companies on reducing the cost of the drug liothyronine.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	205921
answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>The Department has not had any discussions with pharmaceutical companies to reduce the cost of liothyronine tablets.</p><p> </p><p>Liothyronine is an unbranded generic medicine. The Department encourages competition between suppliers of unbranded generic medicines to keep prices down. This generally works well and has led to some of the lowest prices in Europe.</p><p> </p><p>Concerns about anti-competitive behaviour are a matter for the Competition and Markets Authority (CMA) to investigate. Liothyronine, marketed by Concordia, is currently the subject of an investigation by the CMA, which has provisionally found that Concordia abused its dominant position to overcharge the National Health Service by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.</p><p> </p><p>The Department also has its own powers to limit prices of unbranded generic medicines and will consult early in 2019 with the relevant industry bodies on implementation of those powers.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 16:03:08 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

1037139

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rare Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the availability of treatments for patients with rare diseases since the introduction of the Orphan Medical Product Regulation 2000.
tabling member constituency	Bury North
tabling member printed	James Frith
uin	206027
answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>The Government is committed to improving the lives of all those affected by a rare disease. Implementation plans by NHS England and the Department were published jointly in January 2018 and describe the actions and framework in place to deliver this commitment to improve the lives of those affected by rare disease, as defined in the UK Strategy for Rare Diseases.</p><p> </p><p>Through its technology appraisal and highly specialised technologies programmes, the National Institute for Health and Care Excellence (NICE) plays an important role in ensuring that patients, including patients with rare diseases, are able to benefit from effective new treatments. NICE has recommended a number of drugs for rare diseases through these programmes that are now routinely funded by the National Health Service for eligible patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 16:13:10 answering member 4067 label Biography information for Steve Brine
tabling member	4637 label Biography information for James Frith

1037231

registered interest
date	07/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if his Department will increase the number of places on the pre-exposure prophylaxis impact trial.
tabling member constituency	Bermondsey and Old Southwark
tabling member printed	Neil Coyle
uin	205957
answer	answer is ministerial correction date of answer 15/01/2019 answer text <p>The Department recognises the importance of the pre-exposure prophylaxis (PrEP) impact trial. NHS England has announced its support for expansion of the trial and we are actively considering the next steps in relation to PrEP. We will make an announcement on this as soon as possible.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/01/2019 16:13:52 answering member 4067 label Biography information for Steve Brine
tabling member	4368 label Biography information for Neil Coyle

1035112

registered interest
date	04/01/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make an assessment of the implications for his policies of the report entitled, Global Action Plan for the Prevention and Control of NCDs 2013-2020, published by the World Health Organisation; and if he will make statement.
tabling member constituency	South West Bedfordshire
tabling member printed	Andrew Selous
uin	205213
answer	answer is ministerial correction date of answer 09/01/2019 answer text <p>The Government supports the World Health Organization’s (WHO) ‘Global Action Plan for the Prevention and Control of NCDs 2013-2020’ and has implemented a range of policies which contribute to reducing and controlling non-communicable diseases (NCDs). These include policies to reduce smoking; promote healthy diets; tackle misuse of alcohol; and encourage physical exercise. All of these policies are well-aligned with the WHO’s recommended actions on NCDs.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 09/01/2019 15:14:44 answering member 4067 label Biography information for Steve Brine
tabling member	1453 label Biography information for Andrew Selous